There have been many reports suggesting that soluble oligomers of amyloid (A) are neurotoxins causing Alzheimer's disease (AD). Although inhibition of the soluble oligomerization of A is considered to be effective in the treatment of AD, almost all peptide inhibitors have been designed from the -sheet structure (H14-D23) of A 1-42 . To obtain more potent peptides than the known inhibitors of the soluble-oligomer formation of A 1-42 , we performed random screening by phage display. After fifth-round panning of a heptapeptide library against soluble A 1-42 , novel peptides containing arginine residues were enriched. These peptides were found to suppress specifically 37/48 kDa oligomer formation and to keep the monomeric form of A 1-42 even after 24 h of incubation, as disclosed by SDS-PAGE and size-exclusion chromatography. Thus we succeeded in acquiring novel efficient peptides for inhibition of soluble 37/48 kDa oligomer formation of A 1-42 .
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The aggregation processes of proteins into amyloid fibrils are complicated, and the aggregated proteins are in some cases associated with neurodegenerative diseases such as AD. 1) AD is marked by aggregated fibrils of amyloid protein (A), which are the main components of plaque in the brain tissues of AD patients.
2) A is derived from amyloid precursor protein (APP) due to the action of -and -secretase, and it consists of 40 or 42 amino acids. Although the A of 40 residues is the major product in the hydrolysis of APP, the A of 42 residues (A 1-42 , molecular weight ¼ 4514.04 Da) is easier to aggregate than the A of 40 residues, and fibrils of A are deposited mainly in the brain tissue. 1) Recent studies have suggested that the soluble oligomers of A 1-42 might be more toxic to neuronal cells than fibrils at the early stage of AD. [3] [4] [5] Those oligomers consist of an A-derived diffusible ligand (17-42 kDa), 3) A Ã 56 (56 kDa), 4) and globulomer (37/48 kDa, apparent mass of the two bands on SDS-PAGE gel). 5) Among these soluble oligomers, we chose the 37/48 kDa oligomers as the target of an inhibition study for the following reasons. First, the 37/48 kDa oligomers can be homogeneously and reproducibly prepared by using detergent or fatty acids in vitro.
5) Second, these oligomers have been reported to be neuropathological proteins at the early stage of AD, and are present in the brains of patients with AD. 5) They bind specifically to the hippocampal neurons. These oligomers completely block long-term potentiation in rat hippocampal slices. This evidence suggests that these soluble oligomers are formed at an early pathological stage in AD. Hence inhibition of soluble 37/48 kDa oligomers formation of A 1-42 is expected to be an effective approach to the treatment of AD.
Several groups have found peptides for inhibition of A assemblies. 6, 7) The deca-peptide (KQKLLLFLEE) was designed from the H14-D23 region of A by Takahashi and Mihara. 6) Although it prevented the accumulation of soluble-oligomer formation by promoting the fibrillation process, it has never been found to inhibit soluble 37/48 kDa oligomer formation. Also, Soto et al., have designed a penta-peptide (LPFFD) from the hydrophobic core (K16-F20) of A. 7) Although it inhibits fibril formation and disassembles the fibrils of A, it has never been found to inhibit the soluble 37/48 kDa oligomers formation.
In this study, we decided to use a random peptide library to obtain novel peptide inhibitors specific against the soluble 37/48 kDa oligomer formation of A 1-42 . There were two reports in 2006 that peptides inhibiting the oligomerization of A were searched for using phage displays. 8, 9) Those peptides were targeted to the -sheet structure of A, and exhibited major inhibitory effects on the fibrils formation, but not on soluble oligomers. We constructed a different random library (XX-P-XXXX) based on those reports. Proline was introduced in the sequences because it can be considered to be an important factor as a -sheet breaker peptide, LPFFD. 7) To expand the binding region of LPFFD, we added one amino acid to the N-and C-terminals. We found that the peptides obtained were novel sequences containing common arginine residues, and had clear inhibitory effects on soluble 37/48 kDa oligomer formation.
Materials and Methods
Materials. A 1-42 was purchased from Peptide Institute (Osaka, Japan). T7Select Cloning Kit containing T7Select415-1b phage vector, T7 Packaging Extracts, BL21 glycerol stocks, T7SelectUP primer, and T7SelectDOWN primer were from Novagen (Madison, USA). Glutaraldehyde 25% solution, amino ethanol, HFIP, DMSO, polyethylene glycol, sodium dodecyl sulfate (SDS), o-phenylenediamine, and y To whom correspondence should be addressed. Tel: +81-3-5452-6272; Fax: +81-3-5452-6274; E-mail: kamijo@iis.u-tokyo.ac.jp Abbreviations: A, amyloid protein; AD, Alzheimer's disease; ELISA, enzyme-linked immunosorbent assay; HFIP, hexafluoroisopropyl alcohol; KQ, KQKLLLFLEE; LP, LPFFD; ThT, thioflavine T; SEC, size-exclusion chromatography thioflavine T were from Nacalai Tesque (Kyoto, Japan). Anti-T7tail antibody was from Novagen. Anti-IgG-HRP conjugate was from KPL. A Superdex75 column and calibration-marker proteins were from GE Healthcare (Tokyo, Japan). A microplate for ELISA, Nunc Immobilizer (amino), was from Thermo Fisher Scientific (Yokohama, Japan).
Construction of a random peptide T7 phage library. A peptide library was constructed on T7 phage following the manual from Novagen. Random DNA fragment (NNK) 2 -CCT-(NNK) 4 was amplified using CCGAATTCA-GGT-GGA-GGC-TCA-GGT-GGA-GGC-TCA-NNKNNK-CCT-NNKNNKNNKNNK-GGC-TAA-AAGCTTGC-GGC as template (GAATTC: EcoRI; AAGCTT: HindIII, TAA: stop codon). The PCR primers were as follows: forward: CCGAATTCA-GGTGGAGGCTC, and reverse: GCCGCAAGCTTTTAGCC. The amplified fragment was inserted into the corresponding restriction sites in the T7Select415-1b phage vector, and the ligated solution was mixed with T7 Packaging Extracts. The resulting phage was used to infect E. coli BL21, amplified, and isolated using polyethylene glycol.
Preparation of soluble oligomers and fibrils of A . A 1-42 protein (0.56 mg) was dissolved in 0.27 ml of HFIP and dried in vacuo. The dried pellet was re-dissolved in DMSO at 500 mM as stock solution. To prepare soluble A, the stock solution was immediately diluted by PBS to 5.0 mM (DMSO: 1%), and was used in panning and in ELISA. To prepare water-soluble oligomers, the stock solution was diluted with PBS to 100 mM (DMSO: 20%), and this was incubated with 0.1% SDS at 37 C for 4 h in the absence and the presence of peptides (0.1-1.2 mM). These solutions were applied to SDS-PAGE (5-20%) or loaded on a gel-filtration column, as described below. For fibril preparation, the A solution (0.1 mM, DMSO: 20%) in PBS was incubated at 37 C for 24 h.
Panning method. Panning against soluble A 1-42 proceeded as follows: On a Nunc immobilizer (amino) plate, glutaraldehyde (1% ¼ 0:1 M in water) was first immobilized for 1 h at room temperature. Then 50 ml of the soluble state of the A 1-42 solutions (5.0 mM in PBS, DMSO: 1%) was added to the aldehyde-modified surface for 1 h at room temperature. Next, amino ethanol (0.2 M in PBS), as blocking reagent, was added to the surface and left for 1 h at room temperature. A T7 phage library (about 4 Â 10 8 pfu (plaque forming unit)) prepared by this method was added to the well and left for 1 h at room temperature, and the well was washed with PBS with 0.1% Tween20 (PBST) 5 times. Then E. coli BL21 was added directly and cultured in the well for 3 h at 37 C to amplify the phages. The phages, recovered from the culture supernatants by polyethylene glycol precipitation, were used in the next round panning.
ELISA analyses. The phage solution (50 ml, approximately 10 8 pfu) was added to A 1-42 immobilized microwell for 1 h at room temperature. After the well was washed with PBST 4 times, anti-T7-tail antibody (1/500 dilution) was added and this was left for 1 h at room temperature. Then anti-IgG-HRP conjugate (1/100 dilution) was added under the same conditions. Fifty ml of substrate solution (3.7 mM o-phenylenediamine, 0.2 M citrate phosphate buffer pH 5.0, and 0.024% H 2 O 2 ) was added, and the binding signals were detected by measuring the absorbance at 492 nm after a 10-min reaction using a microplate reader MTP800AFC from Corona (Ibaragi, Japan). When the phage solution, giving about 10 8 plaques, was immobilized on the plate, the ELISA signal was measured at 1.8 Abs. Based on this relation between the absorbance and the phage plaques, the percentage of the phage bound to A 1-42 at each panning round was estimated.
Size-exclusion chromatography (SEC). To detect the soluble oligomers of A 1-42 , a Superdex75 column (10 Â 300 mm) was used. Protein samples (100 ml) were centrifuged at 12,000 rpm for 10 min at 4 C, and the resulting supernatants were diluted with PBS to 500 ml. The solutions were loaded on the column, and the proteins were detected at 280 nm on AKTA prime plus (GE Healthcare) at 4 C. PBS was used as the elution buffer. The following proteins were used as calibration markers for molecular weight: conalbumin (75 kDa), carbonic anhydrase (29 kDa), ribonuclease (13.7 kDa), and aprotinin (6.5 kDa).
ThT assay. Amyloid fibrils were detected using ThT fluorometric reagent based on a reported method.
10) The solution, containing A 1-42 , was diluted to a final concentration of 2 mM in PBS and combined with 10 mM ThT reagent. After 2 min of incubation at room temperature, the fluorescent intensity was measured at 492 nm using an excitation wavelength of 450 nm on microplate reader MTP800AFC (Corona).
DNA sequencing. After the fifth round of panning, the phage plaque was prepared on an LB plain plate following the T7Select System Manual. Phage clones giving DNA bands consistent with the theoretical lengths of the peptides were selected by plaque PCR using primers (T7Select UP primer, T7Select DOWN primer). The amplified DNA fragments with the UP primer were provided to fasmac (Atsugi, Japan) for analysis of the DNA sequences.
Peptides. The peptides were purchased from HiPep Laboratories (Kyoto, Japan). The LC-MS data for the synthesized peptides are described in the Supplemental data (see Biosci. Biotechnol. Biochem. Web site).
Results

Selection of peptides binding to soluble A 1-42
We constructed a hepta-peptide library on T7 phage and repeated the panning process against immobilized A 1-42 5 times. As shown in Fig. 1A , phages bound to A 1-42 (black bar) were gradually enriched, as compared with those bound to the control milk solutions (white bar) as the number of panning rounds increased. About 60% of total input phages (approximately 10 8 plaques) were found to bind to A 1-42 after the fifth round. Sequence analysis after the fifth round of panning revealed that most of the binding phages contained arginine residues in common ( Table 1 ). The various phage clones were isolated and tested for binding ability A, ELISA of phage mixture after each round. Milk solution (2%) in PBS was used as control. ELISA signals were detected by measuring the absorbance of 0-phenylenediamine at 492 nm. Percentages of phages bound to A 1-42 at each round were estimated as described in ''Materials and Methods'': about 10% at the first, 30% at the third, and 60% at the fifth round. B, ELISA of phage clones isolated after fifth-round panning against soluble A 1-42 . Phage solutions giving about 10 8 plaques were used. Assays were repeated 3 times, and the average values are given.
to A (Fig. 1B) . The phage clones (nos. 2, 4, 5, 6, and 8) bound more strongly than the other clones (nos. 1, 3, and 7). The strong binders contained three-arginine residues, and especially, nos. 2, 4, 5, and 6 contained repeat sequences of Arg-Arg. The weak binders (nos. 1, 3, and 7) contained one or two arginines. Although the reason for the enrichment of the arginine residues is not fully understood, highly cationic sequences containing at least three arginine residues are probably important in binding to the soluble A 1-42 structure, because arginine contains a basic guanidine group. Next, the no. 8 peptide was used in an inhibition test against soluble 37/48 kDa oligomer formation of A 1-42 , because it was the strongest binder to soluble A 1-42 .
Inhibition of soluble-oligomer formation by the binding peptides
Barghorn et al. have reported a method of producing soluble oligomers of A 1-42 in vitro.
5) Those oligomers were produced by incubation of A 1-42 (0.1 mM) with SDS (0.1%) in PBS, and mainly contained 37/48-kDa oligomeric forms and low-molecular weight oligomers of about 21 kDa in the SDS-PAGE gel (lane b in Fig. 2A and B, see also Supplemental data at the Biosci. Biotechnol. Biochem. Web site). The low-molecular weight oligomers appeared to consist of tetramer and pentamer, and were seen even at 0-h of incubation in the SDS-PAGE gel (lane a). When A 1-42 was incubated with SDS (0.1%) at 37 C for 4 h, 37/48 kDa oligomers were produced, and tetramers and A 1-42 monomer were decreased (lane b). It is estimated that tetramers are origomerized to 37/48 kDa oligomers, but pentamers can exist stably under the (þ) SDS condition. The influence of no. 8 peptide (RGPRGRV) on the formation of the soluble oligomers of A 1-42 was compared with those of known peptide inhibitors, KQKLLLFLEE (the KQ peptide) and LPFFD (the LP peptide). The KQ peptide was designed from the -sheet structure (H14-D23) of A, 6) and the LP peptide from the central hydrophobic core (KLVFF) of A. 7) Incubation of A 1-42 (0.1 mM) with the no. 8 peptide (0.4 mM) in the presence of 0.1% SDS drastically reduced the bands around 37/48 kDa (lane c in Fig. 2A ). The monomer band was slightly increased, as compared to the sample without the peptide (lane b). Low-molecular weight oligomers around 21 kDa showed no changes in the intensities of the bands in the gel. Even after 24-h incubation of A 1-42 with the no. 8 peptide, the band corresponding to the A 1-42 monomer was more apparent than the samples with other peptides (lane c in Fig. 2B ). On the contrary, neither the KQ peptide nor the LP peptide (lanes e and f in Fig. 2A and B ) much influenced the formation of soluble 37/48 kDa oligomers of A 1-42 or an unrelated peptide (AHGVTSA) (lane d in Fig. 2A and B) . These results indicate that the no. 8 peptide markedly inhibited soluble 37/48 kDa oligomer formation from the A 1-42 monomer more efficiently than other known peptide inhibitors.
Next, A fibril formation under the (þ) SDS condition was checked by ThT-binding assay (Fig. 2C) . Solutions containing A 1-42 (0.1 mM) with peptides (0.4 mM) and 0.1% SDS were incubated at 37 C for 24 h. A fibrils were formed more in the presence of the no. 8 peptide (circle) than in the samples without the peptide (triangle) or with the KQ peptide (square) under 10-h of incubation. Although the amounts of fibrils in the three samples were almost the same at 24-h of incubation, the A 1-42 monomer with the no. 8 peptide remained in greater quantity in the lane of the SDS-PAGE gel (lane c in Fig. 2B ). These results indicate that the no. 8 peptide inhibited 37/47 kDa oligomer formation from A 1-42 monomer, rather than it promoted A fibrillation.
We also tested the inhibition effect of the no. 8 peptide on A fibrillation under the (À) SDS condition by ThT binding assay. After A 1-42 (0.1 mM) was incubated with peptides (no. 8, an unrelated peptide, and KQ, each at 0.5 mM) in PBS at 37 C for 24 h, the florescence intensities in the samples were measured, as described in ''Materials and Methods.'' The data obtained were as follows: 130 AU in the case of A 1-42 only; 95 AU in the case of A 1-42 with the no. 8 peptide; 125 AU in the case of A 1-42 with the unrelated peptide; and 150 AU in the case of A 1-42 with KQ. These data indicate that the no. 8 peptide inhibited fibrillation, and that KQ promoted fibrillation. The difference in action on A 1-42 between the no. 8 peptide and KQ was also identified by SDS-PAGE analysis (Fig. 2D) . When A 1-42 (0.1 mM) was incubated at 37 C for 24 h without peptides, low-molecular-weight oligomers and the A 1-42 monomer were considerably decreased (lane a (0 h) and lane b (24 h)). On the other hand, the A 1-42 monomer remained in significant quantity in the solution containing A 1-42 with the no. 8 peptide (lane c) than in the other solutions (lanes d and e). This indicates that the no. 8 peptide has strong ability to keep the A 1-42 monomeric form.
The inhibition effect of the no. 8 peptide on the 37/ 48 kDa oligomers was also disclosed by SEC analysis (Fig. 3A) . After incubation of A 1-42 (0.1 mM) with the no. 8 peptide (at 0, 0.2, and 0.4 mM) and 0.1% SDS at 37 C for 4 h, the solutions were subjected to a Superdex75 column. Soluble oligomers of A 1-42 were detected as broad peaks, between 29 kDa and 75 kDa of the calibration markers (see also the Supplemental data), and low-molecular weight oligomers was detected at about 15 kDa. The no. 8 peptide (0.2 and 0.4 mM) decreased the amounts of the soluble oligomers (37/ 48 kDa) of A 1-42 to below half, but little affected the low-molecular weight peak. These results confirm that the no. 8 peptide specifically interferes with the process from the A 1-42 monomer to the 37/48 kDa oligomers, but does not affect low-molecular weight oligomer formation.
Next, the dose-effects of the peptide on the inhibition of soluble oligomer formation were examined in detail. A 1-42 (0.1 mM) was incubated with various concen- 
The binding phages were amplified and subjected to plaque PCR, followed by DNA sequencing, as described in ''Materials and Methods.'' trated the no. 8 peptides (0.1-1.2 mM) in the presence of SDS (0.1%) at 37 C for 4 h. As found in the SDS-PAGE gel (Fig. 3B) , soluble 37/48 kDa oligomers were decreased and a monomer band of A 1-42 below 10 kDa apparently remained as evidence of increasing peptide concentrations (lanes d-g) . In the case of a 0.1 mM concentration of the peptide, 37/48 kDa oligomer formation was not inhibited (lane c). This indicates that the inhibitory effect of the peptide on 37/48 kDa oligomers is very weak when the molar ratio of A 1-42 to the peptide is one-to-one. This suggests that soluble 37/ 48 kDa oligomer formation can be inhibited by binding of at least two molecules of the peptide to A 1-42 .
Finally, the other peptides (nos. 2, 4, 5, 6, and 7) were also tested for inhibition of soluble oligomer formation of A 1-42 by SDS-PAGE analysis (Fig. 4) . All peptides (nos. 2, 4, 5, and 6, at 0.4 mM) except for no. 7 (lanes b-e) yielded decreases in soluble 37/48 kDa oligomer like no. 8 (lane g). The no. 7 peptide (lane f) inhibited the 37/48 kDa oligomer formation less than the above peptides. The no. 7 peptide was a weaker binder to the soluble A 1-42 than the other peptides, as found by phage-ELISA (Fig. 1B) . Although some peptides (no. 1 and no. 3) have not yet been tested, these results indicate that strong binders to soluble A 1-42 are potent inhibitors of the 37/48 kDa oligomer formation of A 1-42 . 
Discussion
Several peptides have been developed by other groups to inhibit the aggregation of A. [6] [7] [8] [9] Because the aggregation process is believed to be driven by -sheet assemblies, 11) many peptides have been specifically designed from the hydrophobic -sheet core of A, and exhibit major inhibitory effects only on the fibrillation. A representative peptide inhibitor, LP peptide, was designed to inhibit fibril formation, 7) but it little affected soluble 37/48 kDa oligomer formation. Although the KQ peptide was reported by Mihara et al. to trap soluble oligomers in the course of fibrillation, 6) it has not been found to inhibit the soluble 37/48 kDa oligomer formation of A . On the contrary, the peptides (nos. 2, 4, 5, 6, and 8, Table 1 ) found in this study inhibited the 37/48 kDa oligomer formation of A 1-42 . These peptides are the first examples of inhibition of soluble oligomer (37/48 kDa) formation of A 1-42 . Our peptides were selected from a random library constructed based on the LPFFD sequence. Although the LPFFD is hydrophobic peptide, the peptides found in this study were rather hydrophilic due to arginine residues. Probably, both the cationic character and the proline residue as a -sheet breaker are necessary for inhibition of 37/48 kDa A 1-42 oligomer formation. How do the peptides bind to the soluble A protein? If arginine residues are important for binding of the peptide to soluble A 1-42 , the cationic species of basic guanidine groups may play roles in the interaction between the peptide and A 1-42 , because A 1-42 contains negatively charged amino acids such as aspartic acids (D1, D7, and D23) and glutamic acids (E3, E11, and E22).
12) Yu et al. described the structural difference between the soluble oligomers of A 1-42 and the fibrils of A 1-42 , and suggested that residues between D23 and A30 are involved in the formation of the turn structure and are critical in determining alternative conformations of A 1-42 . 13 ) As for the turn structure, Masuda et al. suggested that the toxic conformation of A 1-42 might form a turn structure at positions 22 and 23, based on solid-state NMR experiments. 14, 15) From these structural analyses, it can be estimated that the peptides bind to E22-D23 and break the turn structure, resulting in inhibition of the conformational change in A 1-42 .
Another possible binding region of the peptides to A 1-42 is the contact region between the As in the oligomerization state, but the detailed structures of the 37/48 kDa oligomers have not yet been elucidated, and so the contact region cannot be further discussed. A study of the peptide-binding region of the A protein should be performed in the near future. Recent studies suggest that soluble oligomers of A 1-42 are highly toxic at an early pathological stage in AD. [3] [4] [5] Inhibition of soluble-oligomer formation is an effective approach to the treatment of AD. We have succeeded in finding peptides that can inhibit specifically 37/48 kDa oligomer formation among several soluble oligomers of A . We expect that developments in effective therapeutics for AD will be accelerated using these peptides. 
